Last update Dec. 25, 2021
Very Low Risk
Macrolide with actions and uses similar to those of erythromycin. Oral administration once a day.
Excreted in very low levels into breast milk (Sutton 2015, Salman 2015, Kelsey 1994) and no problems have been observed in infants whose mothers have taken it. (Goldstein 2009)
Commonly used for pediatric treatment.
Expert authors consider Azithromycin compatible with breastfeeding. (Butler 2014, Kong 2013, Khrianin 2010, Chen 2010, Goldstein 2009, Mahadevan 2006, Bar-Oz 2003, Chin 2001)
Early exposition (first 15 days of life) to Macrolides (mostly Erythromycin) have been related to hypertrophic pyloric stenosis (Lund 2014, Maheshwai 2007, Sørensen 2003), but not others, including two meta-analysis (Almaramhy 2019, Abdellatif 2019). This association has not been observed with Azithromycin. (Goldstein 2009, Maheshwai 2007).
Although rare, the possibility of transient gastroenteritis due to alteration of the intestinal flora in infants whose mothers take antibiotics should be taken into account. (Benyamini 2005)
We do not have alternatives for Azithromycin since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.